KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Equity Average (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Equity Average for 16 consecutive years, with $6.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 9.69% year-over-year to $6.1 billion, compared with a TTM value of $6.1 billion through Dec 2025, up 9.69%, and an annual FY2025 reading of $5.9 billion, up 10.7% over the prior year.
  • Equity Average was $6.1 billion for Q4 2025 at Biomarin Pharmaceutical, roughly flat from $6.0 billion in the prior quarter.
  • Across five years, Equity Average topped out at $6.1 billion in Q4 2025 and bottomed at $4.1 billion in Q1 2021.
  • Average Equity Average over 5 years is $4.9 billion, with a median of $4.8 billion recorded in 2023.
  • Peak annual rise in Equity Average hit 29.87% in 2021, while the deepest fall reached 4.56% in 2021.
  • Year by year, Equity Average stood at $4.3 billion in 2021, then rose by 7.56% to $4.6 billion in 2022, then grew by 7.38% to $4.9 billion in 2023, then increased by 12.42% to $5.5 billion in 2024, then increased by 9.69% to $6.1 billion in 2025.
  • Business Quant data shows Equity Average for BMRN at $6.1 billion in Q4 2025, $6.0 billion in Q3 2025, and $5.9 billion in Q2 2025.